Erratum to: Clin Transl Allergy (2017) 7:1 DOI 10.1186/s13601-016-0139-2
Information from the manufacturer of the topical intervention in the GSK2646264 trial outlined in this review [1] indicates that the half-life of the product has not been established with certainty on the available data.
Footnotes
The online version of the original article can be found under doi:10.1186/s13601-016-0139-2.
Contributor Information
Emek Kocatürk, Email: dremekozgur@gmail.com.
Marcus Maurer, Email: marcusmaurer@charite.de.
Martin Metz, Email: martinmetz@charite.de.
Clive Grattan, Email: Clive.E.Grattan@gstt.nhs.uk.
Reference
- 1.Kocatürk E, Maurer M, Metz M, Grattan C. Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy. 2017;7:1. doi: 10.1186/s13601-016-0139-2. [DOI] [PMC free article] [PubMed] [Google Scholar]